Medtech giant Abbott is buying New Brighton-based Cardiovascular Systems Inc. for $890 million, expanding its portfolio in treating artery disease. Cardiovascular Systems (CSI) specializes in ...

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will present data from its CONFIRM study series at the 10 th annual VIVA conference in Las Vegas, Oct. 9–11, 2012.

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

CONFIRM Study Results Highlight Effectiveness of Orbital Atherectomy in Treating PAD CONFIRM is the largest atherectomy dataset ever for PAD—more than 3,100 patients and 4,700 lesions Study ...

Investor Relations, 651-259-2800orSarah Wozniak, 651-259-1636orMatt Sullivan, 612-455-1709orDave Folkens, 612-455-1741 Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company ...

Introduction of Orbital Atherectomy in Canada Expands Treatment Options for Patients with Complex Coronary Artery Disease Dr. Kalra said, “Patients with calcific coronary artery disease can have poor ...

ST. PAUL, Minn., & SAN FRANCISCO--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI) (NAS: CSII) , was featured as part of the "Innovation and Technology Adoption" presentation during the ...

Dr. Tony Das Presented Late-breaking CONFIRM Study Results at VIVA 2012 Highlighting the Effectiveness of Orbital Atherectomy in Hospital and Office Based Lab Setting CONFIRM largest atherectomy ...

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...